Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00232999
Recruitment Status : Completed
First Posted : October 5, 2005
Last Update Posted : July 4, 2012
AllerGen NCE Inc.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

Brief Summary:
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.

Condition or disease Intervention/treatment Phase
Asthma Drug: Nebulized IVX-0142 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : October 2005
Actual Primary Completion Date : December 2005
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Primary Outcome Measures :
  1. Serial lung function tests measured up to 7 hours post-allergen challenge to assess effects on early- and late-phase asthmatic reactions

Secondary Outcome Measures :
  1. Methacholine PC20 pre- and post-allergen challenge
  2. Anti-inflammatory activity in airways

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mild stable allergic asthma
  • Positive skin-prick test to at least one common aeroallergen
  • Positive methacholine challenge
  • Positive allergen-induced early- and late-phase airway bronchoconstriction
  • General good health

Exclusion Criteria:

  • Lung diseases other than mild allergic asthma
  • History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
  • Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
  • Use of tobacco products within one year starting study or smoking history >10 pack years
  • If female, pregnant or lactating or have positive pregnancy test at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00232999

Canada, Ontario
Department of Medicine, McMaster University
Hamilton, Ontario, Canada, L8N 3Z5
Canada, Quebec
Centre de cardiology et de pneumologie de l'Universite Laval
Sainte-Foy (Quebec City), Quebec, Canada, G1V 4G5
Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
AllerGen NCE Inc.
Principal Investigator: Paul M O'Byrne, MD McMaster University and AllerGen NCE

Publications of Results:
Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc. Identifier: NCT00232999     History of Changes
Other Study ID Numbers: IXR-201-04-142
First Posted: October 5, 2005    Key Record Dates
Last Update Posted: July 4, 2012
Last Verified: September 2008

Keywords provided by Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. ):
Allergic asthma
Allergen challenge
Bronchial hyperresponsiveness

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases